Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry

Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry

Abstract The 2019 global coronavirus (COVID-19) pandemic has brought the world to a grinding halt, highlighting the urgent need for therapeutic and preventive solutions to slow the spread of emerging viruses. The objective of this study was to assess the anti-SARS-CoV-2 effectiveness of 8 FDA-approv...

Full description

Bibliographic Details
Main Authors: Margot Morin-Dewaele, Sophie Bartier, François Berry, Rozenn Brillet, Dennis Salomón López-Molina, Công Trung Nguyễn, Pascale Maille, Kevin Sereno, Quentin Nevers, Laurent Softic, Jean-Marie Vaugeois, Bruno Louis, Emilie Bequignon, Patrice Bruscella, André Coste, Jean-Michel Pawlotsky, Stéphane Jamain, Abdelhakim Ahmed-Belkacem
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-25399-5

Internet

https://doi.org/10.1038/s41598-022-25399-5

Similar Items